Evidence of Liver Transplantation Clinical Trial
Verified date | July 2018 |
Source | Fuda Cancer Hospital, Guangzhou |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is the safety and efficacy of cryosurgery plus natural killer(NK) immunotherapy to tumors in transplanted liver.
Status | Completed |
Enrollment | 20 |
Est. completion date | July 1, 2018 |
Est. primary completion date | July 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility |
Inclusion Criteria: - All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence - Body tumor 1-6, the maximum tumor length < 5 cm - KPS = 70, lifespan > 6 months - Platelet count = 80×109/L,white blood cell count = 3×109/L, neutrophil count = 2×109/L, hemoglobin = 80 g/L Exclusion Criteria: - Patients with cardiac pacemaker - Patients with brain metastasis - Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction |
Country | Name | City | State |
---|---|---|---|
China | Cancer Institute of Fuda cancer hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Fuda Cancer Hospital, Guangzhou | Shenzhen Hank Bioengineering Institute |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 3 months | ||
Secondary | Progress free survival(PFS) | 1 year | ||
Secondary | Overall survival(OS) | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02239991 -
Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant
|
N/A | |
Recruiting |
NCT03013634 -
Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation
|
N/A | |
Active, not recruiting |
NCT02579408 -
Quantifying Steatosis in Liver Transplant Donors
|
||
Completed |
NCT02008097 -
Clinical Benefits of B-Flow Ultrasound
|
N/A | |
Completed |
NCT04763096 -
Evaluate the Efficacy and Safety of the ADVAGRAF®
|
Phase 4 | |
Recruiting |
NCT01766518 -
The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)
|
Phase 4 | |
Recruiting |
NCT01607788 -
Prospective Liver Tumor (ProLiT) Database
|
N/A | |
Not yet recruiting |
NCT01860716 -
Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant.
|
Phase 3 | |
Completed |
NCT01022476 -
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
|
Phase 1/Phase 2 | |
Completed |
NCT01546064 -
Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity
|
N/A | |
Completed |
NCT02263703 -
Immunogenicity of HPV Vaccine in Immunosuppressed Children
|
Phase 3 | |
Terminated |
NCT00473824 -
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
|
Phase 2 | |
Terminated |
NCT00151632 -
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT02350218 -
Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)
|
Phase 2 | |
Completed |
NCT02608606 -
Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors
|
N/A | |
Recruiting |
NCT02451046 -
Usefulness of Alpha-GST in Liver Transplantation
|
N/A | |
Completed |
NCT00177931 -
Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit
|
N/A | |
Completed |
NCT01147380 -
Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
|
Phase 1 | |
Terminated |
NCT00694408 -
A Pilot Trial of Pediatric Liver Transplantation Without Steroids
|
Phase 3 | |
Terminated |
NCT00375895 -
Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation
|
Phase 3 |